{"id":"https://openalex.org/W2076999682","doi":"https://doi.org/10.1179/102453312x13336169156375","title":"JAK2 inhibitors and their impact in myeloproliferative neoplasms","display_name":"JAK2 inhibitors and their impact in myeloproliferative neoplasms","publication_year":2012,"publication_date":"2012-04-01","ids":{"openalex":"https://openalex.org/W2076999682","doi":"https://doi.org/10.1179/102453312x13336169156375","mag":"2076999682","pmid":"https://pubmed.ncbi.nlm.nih.gov/22507800"},"language":"en","primary_location":{"id":"doi:10.1179/102453312x13336169156375","doi":"https://doi.org/10.1179/102453312x13336169156375","is_oa":true,"landing_page_url":"https://doi.org/10.1179/102453312x13336169156375","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1179/102453312X13336169156375?needAccess=true&role=button","source":{"id":"https://openalex.org/S195061619","display_name":"Hematology","issn_l":"1024-5332","issn":["1024-5332","1027-7501","1607-8454"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320442","host_organization_name":"Maney Publishing","host_organization_lineage":["https://openalex.org/P4310320442"],"host_organization_lineage_names":["Maney Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.tandfonline.com/doi/pdf/10.1179/102453312X13336169156375?needAccess=true&role=button","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060196258","display_name":"Holly Lynn Geyer","orcid":"https://orcid.org/0000-0002-3963-2350","observed_orcids":["https://orcid.org/0000-0002-3963-2350"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Holly L Geyer","raw_affiliation_strings":["Department of Hospital Internal Medicine","Department of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hospital Internal Medicine","institution_ids":[]},{"raw_affiliation_string":"Department of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA","institution_ids":["https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018041025","display_name":"Raoul Tibes","orcid":"https://orcid.org/0000-0002-1372-8733","observed_orcids":["https://orcid.org/0000-0002-1372-8733"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raoul Tibes","raw_affiliation_strings":["Department of Hematology and Medical OncologyMayo Clinic, Scottsdale, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Medical OncologyMayo Clinic, Scottsdale, AZ, USA","institution_ids":["https://openalex.org/I4210125099"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ruben A Mesa","raw_affiliation_strings":["Department of Hematology and Medical OncologyMayo Clinic, Scottsdale, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology and Medical OncologyMayo Clinic, Scottsdale, AZ, USA","institution_ids":["https://openalex.org/I4210125099"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5039057642"],"corresponding_institution_ids":["https://openalex.org/I4210125099"],"apc_list":{"value":2085,"currency":"GBP","value_usd":2557},"apc_paid":null,"fwci":1.2459,"has_fulltext":true,"cited_by_count":9,"citation_normalized_percentile":{"value":0.81432218,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"17","issue":"sup1","first_page":"s129","last_page":"s132"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/jak2-inhibitors","display_name":"JAK2 inhibitors","score":0.9980000257492065},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.9829999804496765},{"id":"https://openalex.org/keywords/essential-thrombocythemia","display_name":"essential thrombocythemia","score":0.9089999794960022},{"id":"https://openalex.org/keywords/polycythemia-vera","display_name":"polycythemia vera","score":0.9990000128746033},{"id":"https://openalex.org/keywords/primary-myelofibrosis","display_name":"primary myelofibrosis","score":1.0},{"id":"https://openalex.org/keywords/jak-stat-signaling","display_name":"JAK/STAT signaling","score":0.8560000061988831},{"id":"https://openalex.org/keywords/constitutional-symptoms","display_name":"constitutional symptoms","score":0.6790000200271606},{"id":"https://openalex.org/keywords/transfusion-dependence","display_name":"transfusion dependence","score":0.8100000023841858},{"id":"https://openalex.org/keywords/spleen-size-reduction","display_name":"spleen size reduction","score":0.7799999713897705},{"id":"https://openalex.org/keywords/treatment-guidelines","display_name":"treatment guidelines","score":0.7350000143051147}],"concepts":[{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.8658241033554077},{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.7871721982955933},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7393542528152466},{"id":"https://openalex.org/C2781057849","wikidata":"https://www.wikidata.org/wiki/Q1368780","display_name":"Essential thrombocythemia","level":3,"score":0.7250828742980957},{"id":"https://openalex.org/C32465701","wikidata":"https://www.wikidata.org/wiki/Q14914514","display_name":"Janus kinase 2","level":3,"score":0.6225294470787048},{"id":"https://openalex.org/C2781107747","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative neoplasm","level":4,"score":0.6088529825210571},{"id":"https://openalex.org/C2777753580","wikidata":"https://www.wikidata.org/wiki/Q1441305","display_name":"Constitutional symptoms","level":3,"score":0.4916074872016907},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4299785792827606},{"id":"https://openalex.org/C164027704","wikidata":"https://www.wikidata.org/wiki/Q3491837","display_name":"Proinflammatory cytokine","level":3,"score":0.41821280121803284},{"id":"https://openalex.org/C2910274570","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative Disorders","level":2,"score":0.41413044929504395},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4067835211753845},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3113483786582947},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.156462162733078},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.11683142185211182},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000096926","descriptor_name":"Benzenesulfonamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001952","descriptor_name":"Bridged-Ring Compounds","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D001952","descriptor_name":"Bridged-Ring Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002227","descriptor_name":"Carbazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002227","descriptor_name":"Carbazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005663","descriptor_name":"Furans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009196","descriptor_name":"Myeloproliferative Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009196","descriptor_name":"Myeloproliferative Disorders","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D053614","descriptor_name":"Janus Kinase 2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1179/102453312x13336169156375","doi":"https://doi.org/10.1179/102453312x13336169156375","is_oa":true,"landing_page_url":"https://doi.org/10.1179/102453312x13336169156375","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1179/102453312X13336169156375?needAccess=true&role=button","source":{"id":"https://openalex.org/S195061619","display_name":"Hematology","issn_l":"1024-5332","issn":["1024-5332","1027-7501","1607-8454"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320442","host_organization_name":"Maney Publishing","host_organization_lineage":["https://openalex.org/P4310320442"],"host_organization_lineage_names":["Maney Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology","raw_type":"journal-article"},{"id":"pmid:22507800","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22507800","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology (Amsterdam, Netherlands)","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1179/102453312x13336169156375","doi":"https://doi.org/10.1179/102453312x13336169156375","is_oa":true,"landing_page_url":"https://doi.org/10.1179/102453312x13336169156375","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1179/102453312X13336169156375?needAccess=true&role=button","source":{"id":"https://openalex.org/S195061619","display_name":"Hematology","issn_l":"1024-5332","issn":["1024-5332","1027-7501","1607-8454"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320442","host_organization_name":"Maney Publishing","host_organization_lineage":["https://openalex.org/P4310320442"],"host_organization_lineage_names":["Maney Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2076999682.pdf","grobid_xml":"https://content.openalex.org/works/W2076999682.grobid-xml"},"referenced_works_count":13,"referenced_works":["https://openalex.org/W1979648944","https://openalex.org/W2012828222","https://openalex.org/W2015662674","https://openalex.org/W2043781659","https://openalex.org/W2049145190","https://openalex.org/W2087365471","https://openalex.org/W2105496815","https://openalex.org/W2123633897","https://openalex.org/W2253804938","https://openalex.org/W2285901068","https://openalex.org/W2589825320","https://openalex.org/W2590801373","https://openalex.org/W4254201079"],"related_works":["https://openalex.org/W2130365346","https://openalex.org/W2768585710","https://openalex.org/W1979648944","https://openalex.org/W2089429915","https://openalex.org/W1995841484","https://openalex.org/W2530213559","https://openalex.org/W2020412873","https://openalex.org/W2118323591","https://openalex.org/W4388997807","https://openalex.org/W2752296500"],"abstract_inverted_index":{"The":[0,30],"BCR-ABL-negative":[1,40],"myeloproliferative":[2],"neoplasms":[3],"(MPNs)":[4],"include":[5],"essential":[6],"thrombocythemia,":[7],"polycythemia":[8],"vera,":[9],"and":[10,25,70,89,132,143,149],"primary":[11],"myelofibrosis.":[12],"Historically,":[13],"complex":[14],"biochemical":[15],"alterations":[16],"defining":[17],"these":[18,140,152],"heterogeneously":[19],"distinct":[20],"malignancies":[21],"have":[22],"remained":[23],"elusive":[24],"constrained":[26],"available":[27],"therapy":[28],"options.":[29],"discovery":[31],"of":[32,47,98,117,151],"Janus":[33],"kinase":[34],"(JAK)":[35],"mutations":[36],"collectively":[37],"present":[38],"in":[39,50,84,91,146],"MPNs":[41],"has":[42,103],"led":[43],"to":[44,105],"a":[45,59],"resurgence":[46],"medical":[48],"interest":[49],"JAK-STAT":[51],"targeted":[52],"treatment":[53],"modalities,":[54],"as":[55,57],"well":[56],"provided":[58],"unique":[60],"platform":[61],"for":[62,126,134],"inhibiting":[63],"symptom-directing":[64],"proinflammatory":[65],"cytokines.":[66],"INCB018424,":[67],"CYT387,":[68],"SB1518,":[69],"TG101348":[71],"are":[72],"among":[73],"the":[74,113,147],"most":[75],"propitious":[76],"JAK2":[77,118],"inhibitors":[78,119],"under":[79],"investigation,":[80],"providing":[81],"substantial":[82],"improvement":[83],"constitutional":[85],"symptoms,":[86],"transfusion-dependent":[87],"cytopenias,":[88],"reduction":[90],"spleen":[92],"size.":[93],"Despite":[94],"their":[95],"attributes,":[96],"evidence":[97],"complete":[99],"or":[100],"partial":[101],"remission":[102],"yet":[104],"be":[106],"observed":[107],"with":[108],"therapy.":[109],"Many":[110],"uncertainties":[111],"surrounding":[112],"full":[114],"clinical":[115],"potential":[116],"persist.":[120],"Treatment":[121],"guidelines":[122],"addressing":[123],"optimal":[124],"stages":[125],"drug":[127],"implementation,":[128],"ideal":[129],"dosing":[130],"parameters":[131],"criteria":[133],"medication":[135],"continuation/withdrawal":[136],"may":[137],"effectively":[138],"resolve":[139],"ongoing":[141],"concerns":[142],"provide":[144],"advancements":[145],"morbidity":[148],"mortality":[150],"multifaceted":[153],"disease":[154],"processes.":[155]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}